Session Chair Profile

M.D., Ph.D., Institute Director and Distinguished Professor, UCSF; Chief Data Scientist, University of California Health System

Biography
Atul Butte is the Priscilla Chan and Mark Zuckerberg Distinguished Professor and Director of the Bakar Computational Health Sciences Institute at UCSF, and is also the Chief Data Scientist for the entire University of California Health System, the tenth largest by revenue in the United States, with 20 health professional schools, 6 academic health centers, and 10 hospitals. Dr. Butte is an inventor on 24 patents and has authored over 200 publications, with research repeatedly featured in the New York Times and Wall Street Journal. Dr. Butte was elected into the National Academy of Medicine in 2015, and was recognized by the Obama Administration as a White House Champion of Change in Open Science in 2013. Dr. Butte is also a co-founder of Personalis (IPO, 2019), providing medical genome sequencing services, Carmenta (acquired by Progenity, 2015), discovering diagnostics for pregnancy complications, and NuMedii, finding new uses for drugs using AI.


 Speaker Profile

Founder and Chairman, Rare Cancer Research Foundation

Biography
Mark Laabs is an entrepreneur who is a founder, advisor, and/or builder of a wide range of organizations which seek to address critical social and environmental problems on five continents. Mark, an ocular melanoma survivor, founded the RCRF to accelerate innovation in rare cancer research by creating shared infrastructure that drives scale and catalyzes research in these understudied and underserved areas. One of its key initiatives, www.pattern.org, enables patient-powered engagement with cancer research through the donation of fresh tissue vital to create disease models necessary to more fully understand each cancer and to identify potential new treatments. Mark is also focused on enabling precision medicine and trial enrollment opportunities for rare cancer patients regardless of location. Mark serves as Managing Partner of Modern Energy Group, with businesses focused on energy efficiency and resources in the United States and Brazil. Previously, he was COO of Soligent Holdings Inc., helped build and later sell Climate Bridge, a clean energy finance company, and was a consultant at McKinsey & Company. Mark graduated as a Robertson Scholar from the University of North Carolina at Chapel Hill and Duke University with a dual degree in International Studies and the Dynamics of Social Change


 Speaker Profile

Pharm.D., Associate Professor, University of Florida

Biography
Rhonda M. Cooper-DeHoff, Pharm.D., M.S., is a graduate of the University of California, San Francisco School of Pharmacy. Dr. Cooper-DeHoff’s area of research interest include hypertension and cardiovascular disease pharmacogenetics, as well as the factors that influence outcomes with antihypertensive and cardiovascular treatments. She also has interest in the area of antihypertensive drug use and adverse metabolic effects including diabetes, as well as the area of dietary supplements. In total, she has over 200 publications and many have been of high impact, helping to define demographic, clinical, metabolic, metabolomic and genetic and pharmacogenetic factors associated with responses to antihypertensive drugs and cardiovascular outcomes with antihypertensive therapy. She is currently conducting research in the area of ‘big data’ science including the use of EHR data from multiple health systems to conduct real world longitudinal surveillance of important blood pressure control and process metrics, as well as preemptive pharmacogenetics testing in multiple therapeutic areas.

Talk
Tracking BP Control Performance and Process Metrics in 25 US Health Systems
BP control (<140/90 mmHg), calculated using real-world data from 25 health systems across the US, averaged 62%, and there was substantial variation by health system (range 44%-74%). A new class of antihypertensive medication was prescribed in only 12% (range 0.6%-25%) of patient visits where BP was uncontrolled BP. When a medication intensification event occurred, subsequent SBP was 15 ± 20 mm Hg lower on average (range 5-18 mm Hg). Major opportunities exist for improving BP control and reducing disparities.


 Speaker Profile

Ph.D., Chief Scientific Officer, IQVIA; Adjunct Professor, University of North Carolina at Chapel Hill

Biography
Her current work is focused on regulatory use of real-world evidence for decision making. She leads IQVIA’s Center for Advanced Evidence Generation, where they develop and implement innovative approaches to minimally interventional and non-interventional studies. She also directs a large community-based registry designed to study COVID-19. A Fellow of both the Drug Information Association (DIA) and the International Society of Pharmacoepidemiology, she is widely known for her thought leadership, particularly in terms of understanding when real-world evidence is fit for purpose. She received DIA’s 2019 Global Inspire Award for Author of the Year for “Advancing a framework for regulatory use of real world evidence: When real is reliable,” and is an elected member of DIA’s Scientific Advisory. She served for many years as a standing consultant to the National Football League Health & Safety Executive Committee, and continues to lead work on injury analytics for NFL and NBA.

Talk
Real-world Evidence Offers a Path to Precision Medicine
Advances in precision medicine will come from capturing and aggregating vast amounts of data about molecular markers, treatments and outcomes that can be used to shape insights about comparative treatment effectiveness and dosing schedules, but how do we know what evidence we can trust and when?